FDA's Center for Biologics Evaluation and Research (CBER) regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products.
CBER’s research program must keep pace with the rapid innovation in biologics to ensure that CBER’s regulatory decisions and policy-making are informed by the latest science and technology. To achieve this goal, CBER will continue to maintain a robust scientific infrastructure to support key scientific activities by ensuring that CBER’s labs and core research facilities remain up to date with emerging technology.
Goal 2: Conduct Research to Address Challenges in the Development and Regulatory Evaluation of Medical Products
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons.